Patient characteristics
| Patient no. . | Sex . | Age, y . | Time from diagnosis . | Prior treatments . | Associated diagnoses . |
|---|---|---|---|---|---|
| 001 | F | 50 | 10 y | Pred, spl, IVIg, vcr, vbl, HD-dex, PrA-abs, anti-D, dzl, azathioprine | – |
| 002 | F | 42 | 21 y | Pred, spl, IVIg, CVP, colchicine, HD-dex | – |
| 003 | F | 52 | 3 y | Pred, spl, IVIg, dzl, anti-D | Sarcoidosis |
| 004 | M | 17 | 12 y | Pred, spl, IVIg, azathioprine, dzl, IFN, PrA-abs | – |
| 005 | F | 52 | 40 y | Pred, spl, IVIg, plasmapheresis, vbl, CVP | Antecedent Hashimoto thyroiditis, Evans syndrome |
| 006 | F | 32 | 4 y | Pred, spl, dzl, IVIg, anti-D, LD-CTX, vbl, PrA-abs | – |
| 007 | F | 22 | 7 y | Pred, spl, IVIg, CsA, HD-dex | – |
| 008 | M | 46 | 10 y | Pred, spl, PrA-abs, IVIg, CsA, vcr, dzl, LD-CTX, anti-D | Evans syndrome |
| 009 | M | 33 | 6 y | Pred, spl, dzl, IVIg, vbl, col, vcr, CsA, plasmapheresis, PrA-abs, LD-CTX, HD-CTX, HD-MP, MMF | Evans syndrome |
| 010 | M | 43 | 1 y | Pred, spl, vcr, dzl, IVIg | – |
| 011 | M | 34 | 6 mo | Pred, IVIg, spl, rituximab, plasma exchange, LD-CTX, dzl | – |
| 012 | M | 44 | 12 y | Pred, IVIg, spl, CsA, anti-D, MMF ± MP | Evans syndrome |
| 013 | F | 42 | 16 y | Pred, IVIg, spl, dzl, CVP, CsA, rituximab | Evans syndrome |
| 014 | F | 37 | 9 mo | Pred, IVIg, spl, anti-D, dapsone, vcr, LD-CTX, Helicobacter pyloritreatment | – |
| Patient no. . | Sex . | Age, y . | Time from diagnosis . | Prior treatments . | Associated diagnoses . |
|---|---|---|---|---|---|
| 001 | F | 50 | 10 y | Pred, spl, IVIg, vcr, vbl, HD-dex, PrA-abs, anti-D, dzl, azathioprine | – |
| 002 | F | 42 | 21 y | Pred, spl, IVIg, CVP, colchicine, HD-dex | – |
| 003 | F | 52 | 3 y | Pred, spl, IVIg, dzl, anti-D | Sarcoidosis |
| 004 | M | 17 | 12 y | Pred, spl, IVIg, azathioprine, dzl, IFN, PrA-abs | – |
| 005 | F | 52 | 40 y | Pred, spl, IVIg, plasmapheresis, vbl, CVP | Antecedent Hashimoto thyroiditis, Evans syndrome |
| 006 | F | 32 | 4 y | Pred, spl, dzl, IVIg, anti-D, LD-CTX, vbl, PrA-abs | – |
| 007 | F | 22 | 7 y | Pred, spl, IVIg, CsA, HD-dex | – |
| 008 | M | 46 | 10 y | Pred, spl, PrA-abs, IVIg, CsA, vcr, dzl, LD-CTX, anti-D | Evans syndrome |
| 009 | M | 33 | 6 y | Pred, spl, dzl, IVIg, vbl, col, vcr, CsA, plasmapheresis, PrA-abs, LD-CTX, HD-CTX, HD-MP, MMF | Evans syndrome |
| 010 | M | 43 | 1 y | Pred, spl, vcr, dzl, IVIg | – |
| 011 | M | 34 | 6 mo | Pred, IVIg, spl, rituximab, plasma exchange, LD-CTX, dzl | – |
| 012 | M | 44 | 12 y | Pred, IVIg, spl, CsA, anti-D, MMF ± MP | Evans syndrome |
| 013 | F | 42 | 16 y | Pred, IVIg, spl, dzl, CVP, CsA, rituximab | Evans syndrome |
| 014 | F | 37 | 9 mo | Pred, IVIg, spl, anti-D, dapsone, vcr, LD-CTX, Helicobacter pyloritreatment | – |
Pred indicates prednisone; spl, splenectomy; IVIg, intravenous immunoglobulin; vcr, vincristine; vbl, vinblastine; HD-dex, high-dose (pulse) dexamethasone; PrA-abs, plasmapheresis with protein A immunoabsorption; anti-D, anti-Rh(o)D antibody; dzl, danazol; —, no associated diagnosis; CVP, combination cyclophosphamide, vincristine, prednisone; IFN, interferon-α; LD-CTX, low-dose (oral) cyclophosphamide; CsA, cyclosporine A; col, colchicine; HD-CTX, high-dose cyclophosphamide; HD-MP, high-dose (pulse) methylprednisolone; MMF, mycophenolate mofetil; and MP, methylprednisolone.